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Abstract
PAKs are serine/threonine kinases that regulate cytoskeletal dynamics and cell migration. PAK1 is activated by binding to
the small EF hand protein, CIB1, or to the Rho GTPases Rac1 or Cdc42. The role of PAK1 in angiogenesis was established
based only on in vitro studies and its role in angiogenesis in vivo has never been examined. Here we tested the hypothesis
that PAK1 is an essential regulator of ischemic neovascularization (arteriogenesis and angiogenesis) and wound healing
using a global PAK1 knockout mouse. Neovascularization was assessed using unilateral hindlimb ischemia. We found that
plantar perfusion, limb use and appearance were not significantly different between 6–8 week old PAK12/2 and PAK1+/+
mice throughout the 21-day period following hindlimb ischemia; however a slightly delayed healing was observed in 16
week old PAK12/2 mice. In addition, the wound healing rate, as assessed with an ear punch assay, was unchanged in
PAK12/2 mice. Surprisingly, however, we observed a notable increase in PAK2 expression and phosphorylation in ischemic
gastrocnemius tissue from PAK12/2 but not PAK1+/+ mice. Furthermore, we observed higher levels of activated ERK2, but
not AKT, in ischemic and non-ischemic muscle of PAK12/2 mice upon hindlimb ischemic injury. A group I PAK inhibitor,
IPA3, significantly inhibited endothelial cell sprouting from aortic rings in both PAK12/2 and PAK1+/+ mice, implying that
PAK2 is a potential contributor to this process. Taken together, our data indicate that while PAK1 has the potential to
contribute to neovascularization and wound healing, PAK2 may functionally compensate when PAK1 is deficient.
Citation: Elsherif L, Ozler M, Zayed MA, Shen JH, Chernoff J, et al. (2014) Potential Compensation among Group I PAK Members in Hindlimb Ischemia and Wound
Healing. PLoS ONE 9(11): e112239. doi:10.1371/journal.pone.0112239
Editor: Rudolf Kirchmair, Medical University Innsbruck, Austria
Received August 19, 2013; Accepted October 14, 2014; Published November 7, 2014
Copyright:  2014 Elsherif et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institute of Health grants 5R01HL092544 (LVP), 01CA148805 (JC) and 5R01HL111070 (JF). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: LVP - Assoc Editor: Blood, Consultant: Bayer, BD, Biogen. This
does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* Email: parise@med.unc.edu
Introduction
PAKs are serine/threonine kinases involved in many biological
processes including cell proliferation, motility and angiogenesis [1–
3]. Our laboratory originally identified a specific and direct
regulator of PAK1 function, the small EF hand-containing protein
named CIB1 [4]. CIB1 binds to and activates PAK1 indepen-
dently of small GTPases [4]. Depletion of CIB1 in endothelial cells
results in decreased PAK1 activation and impaired endothelial cell
function [5,6], and we have previously reported that CIB12/2
mice exhibit impaired ischemia-induced angiogenesis in retinal
and hindlimb tissue concomitant with a decrease in PAK1
activation [5]. Therefore, we hypothesized that CIB1’s contribu-
tion to neovascularization in vivo is mediated at least in part by
PAK1.
The group I PAK family, which is comprised of PAKs 1–3, are
involved in all major steps of cell migration from cell polarization
and formation of actin-rich protrusions, to contraction of the cell
body and retraction of the trailing edge [7–10]. The diversity of
activators and targets of PAKs can potentially explain their
involvement in all major steps of cell migration. In addition to
small GTPases and CIB1 [4], PAKs are activated by filamin A
[11], tyrosine kinases [12], PDK1 [13], sphingolipids [14], and Akt
[15]. Group I PAK downstream targets essential to cell migration
include LIM kinase-1 [16], MLCK [17], and MLC [18]. Previous
reports showed that a decrease in PAK1 activation impairs
angiogenesis and tubule formation in human microvascular
endothelial cells (HMEC-1) and in a chick chorioallantoic
membrane assay [2,19]. Furthermore, one or more group I
PAK members regulates endothelial cell migration mediated by
Ang-1, and its activation is necessary for restoring vascular
permeability as the last step in the angiogenesis process that
prepares nascent vessels for perfusion [20,21]. PAK1 is also a
strong stimulator of proliferation and migration, leading to the
aggressive behavior of human cancers [22–29]. All of the
aforementioned studies have established a relationship between
PAK1 function and angiogenesis in vitro, thereby predicting a role
for PAK1 in angiogenesis in vivo. However, PAK1’s role in
angiogenesis in vivo has never been tested. Moreover, the role of
PAK1 in angiogenesis cannot be predicted based on the
apparently normal appearance of PAK12/2 mice, since angio-
genesis defects are often only revealed under stress, such as an
ischemic insult [5,30–33].
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In the present study, we used the PAK1 global knockout mouse
in unilateral hindlimb ischemia (HLI)—a commonly used model
to assess neovascularization–and cutaneous wound healing model,
to assess chronic PAK1 loss on neovascularization and wound
healing. Surprisingly, loss of PAK1 in the mouse did not affect
recovery of hindlimb perfusion after femoral artery ligation, which
is well known to depend on collateral remodeling (arteriogenesis)
and ischemic capillary angiogenesis. Furthermore, wound repair,
which is dependent on injury-induced angiogenesis, was un-
changed in the absence of PAK1 in vivo. These findings suggest
that either a lack of PAK1 contribution or another PAK member
may compensate for loss of PAK1. We therefore measured the
expression of multiple PAK family members in ischemic gastroc-
nemius tissue and found that PAK2 protein was significantly
upregulated in ischemic tissue of PAK12/2 mice. Furthermore,
increased levels of activated ERK2 but not ERK1 or AKT were
observed in PAK12/2 compared to PAK1+/+ mice following
acute ischemic injury. Inhibition of both PAK1 and PAK2 using
the pharmacological inhibitor of all group I PAKs, IPA3, results in
significant reduction in endothelial cell (EC) sprouting from aortic
rings. Our results, therefore, suggest a role for upregulation of
PAK2 as a compensatory mechanism in ischemic neovasculariza-
tion and wound healing in a chronic PAK1 knockout mouse
model. This compensatory mechanism appears to be acting
through the MAPK pathway. Our results, however, do not
determine whether PAK1 contributes to neovascularization in
wild type mice, since such a role might only be revealed with
rapid, acute, inhibition as with a highly selective PAK1 inhibitor
that can be given in vivo, which is currently unavailable.
Material and Methods
Ethics Statement
All experiments were performed in accordance with national
guidelines and regulations and were approved by the University of
North Carolina Institutional Animal Care and Use Committee
(ICUC ID 11–038.0). All surgery was performed under isoflurane
anesthesia. Animals were given analgesic post-operatively and all
efforts were made to minimize suffering.
Animals
Generation of PAK12/2 mice was previously described [34].
All mice used in experiments were backcrossed by our laboratory
for at least 10 generations to the C57BL/6 background. PAK1+/+
littermates were used as PAK2/2 controls for all experiments.
Mice were genotyped using PCR with a previously published
forward and reverse primer set [34]. Animals used were males and
females of 2 age groups, 6–8 weeks and 16 weeks with similar body
weights.
Unilateral HLI
Mice underwent a HLI procedure as previously described
[35,36]. Isoflurane (0.8–1.5%) anesthesia was used during the
procedure and during plantar scanning with laser Doppler.
Animal temperature was maintained at 3760.5uC during surgery
and scanning. To assess neovascularization following a severe form
of HLI, ligation of the femoral artery was performed just distal to
the inguinal ligament and proximal to the bifurcation of the
popliteal artery. The artery was transected between the ligation
points; in addition the superficial epigastric artery was ligated
(Figure S1 A). The artery was also transected proximal to the
caudal epigastric. In addition to the severe form of HLI ischemia,
a milder surgery was performed, consisting of ligation and
transection between the lateral caudal femoral artery and proximal
to the bifurcation of the popliteal artery, plus ligation of the
superficial epigastric (Figure S1 B). Hindlimb ischemia experi-
ments were carried out for a total of 21 days, whereas for the
examination of MAPK and AKT signaling, the severe form of
HLI (Figure S1 A) was performed for 1 hour followed by
euthanasia of the animals and tissue harvest. The antibiotic
(cefazolin, 50 mg/kg im) and analgesic (buprenorphine, 9.9 mg/
kg) were administered following surgery.
Laser-Doppler perfusion imaging
Measurements of plantar perfusion were obtained before and
immediately after surgery (day 0), and on days 3, 7, 14, and 21
after surgery using a scanning laser-Doppler perfusion imager
(model LDI2-IR, Moor Instruments, Wilmington, DE) [35].
Imaging was restricted to a region of interest (ROI) in the hind
paw. All ROIs were drawn by an investigator blinded to the mouse
treatments, and mean velocity within the ROI was normalized to
the area of the ROI. Images were analyzed using MoorLDI PC
software. Results are expressed as the ratio of ischemic to non-
ischemic (I/NI) plantar regions [35].
Hindlimb use and appearance score
On days 3, 7, 14, and 21 after HLI, a designated score was
given for each animal based on hindlimb use using the following
criteria: 0 = normal; 1 = no toe flexion; 2 = no plantar flexion;
and 3 = foot dragging [37,38]. In addition, foot appearance was
also scored using the following criteria: 0 = normal; 1–5 =
cyanosis or loss of nail(s), dependent on the number of nails
affected; 6–10 = partial or complete atrophy of digit(s), dependent
on the number of digits affected; 11 = and partial atrophy of the
forefoot [37]. Higher use and appearance scores correspond to
worse outcomes.
Aortic EC sprouting on Matrigel
Aortic rings from PAK12/2 and PAK1+/+ mice were dissected,
embedded in growth-factor reduced Matrigel matrix and cultured
in 2.5% FBS as previously described [5,39]. EC sprout number
was quantified using phase contrast at days 3 and 5 following
embedding. Numbering and counting of sprouts was performed
according to a method described by Baker et al. [39]. IPA3
(30 mM) was added to culture media starting at day 0 and for a
total of 5 days.
Ear wound assay
Using a metal ear punch (Harvard Apparatus) a 2.0 mm hole
was made in the ears of PAK12/2 and wild type PAK1+/+ mice
[40]. For imaging of the ear, mice were anesthetized with
isoflurane and placed on a flat surface with the ear placed between
2 glass slides. Images were obtained on a Leica-Wild M420
microscope. ImageJ was used to calculate ear-wound diameter on
days 1, 3, 7, 14, 21 and 28 after the ear punch. Results are
expressed as the ratio of (Area day x/Area day 0)6100. On day 28,
mice were anesthetized and the ears were fixed with formalin,
sectioned and stained with Masson’s trichrome.
Western blot and antibodies
Gastrocnemius muscle from the left (non-ischemic) and right
(ischemic) hindlimbs was excised on day 21 after surgery, flash
frozen in liquid nitrogen and stored at 280uC until ready for tissue
homogenization and processing. The following antibodies were
purchased from Cell Signaling Technology, Danvers, MA: PAK1
(#2602), PAK2 (#2608), pPAK2 (Ser20) (#2607), PAK3
(#2609), pan AKT (#4691) phospho-ERK1/2 (Thr202/
PAK1 and PAK2 in Neovascularization and Wound Healing
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Tyr204) (#4377), phosphor-AKT (S473) (#9271) and (T308)
(#4056). GAPDH antibody (sc-25778) was purchased from Santa
Cruz Biotechnologies, Santa Cruz, CA. HRP-conjugated second-
ary antibodies were purchased from GE Healthcare, Waukesha,
WI.
Statistical Analysis
Data were subjected to 2-way ANOVA or the Student t test.
Results
The effect of PAK1 loss on neovascularization following
ischemic injury
To assess the contribution of PAK1 to neovascularization, we
used both mild and severe forms of HLI that induce ischemia to
the muscle tissue supplied by the femoral artery. The severe form
of HLI causes more ischemic damage than the mild form,
especially in certain mouse strains resistant to ischemic injury such
as C57BL6, which is the genetic background of the PAK12/2 and
PAK1+/+ mice. The designation of mild and severe HLI is
described in the Material and Methods section, schematically
presented in Figure S1, and is related to the location of artery
ligation and transection. Initially we examined the effects of mild
HLI on 6–8 week old PAK12/2 mice and found that perfusion
immediately following ligation was not different between
PAK12/2 and PAK1+/+ mice. The level of perfusion immediately
following the surgery, which is primarily dependent on the number
and average diameter of the native collaterals in the thigh, was not
different (Figure S2). This indicates that PAK1 is not involved in
collaterogenesis, a process that occurs during development. In
addition, there was no significant difference in perfusion and use
and appearance scores between PAK12/2 and PAK1+/+ mice
throughout 21 days (Figure S2). Furthermore, 6–8 week-old
PAK12/2 mice subjected to severe HLI showed no differences
compared to PAK1+/+ mice (Figure 1). By contrast examination of
16 week old PAK12/2 mice revealed a slight–albeit not
significant–worsening in recovery of perfusion (Figure 2A and
2D) and use and appearance scores (Figure 2B–C) in PAK12/2
compared to PAK1+/+ mice. This trend appeared between days
three and seven post-surgery and was no longer evident by day 14
and thereafter.
Protein expression of other group I PAK kinases in
ischemic tissue
Group I PAKs have structural and functional similarities, as
well as overlapping tissue expression. To explore potential PAK1
compensatory mechanisms we evaluated expression of PAK2 and
PAK3 in ischemic gastrocnemius tissue from mice subjected to
HLI at day 21 (Figure 3A–B). A two-fold increase in PAK2
protein expression was observed in the ischemic hind-limb
gastrocnemius muscle tissue from PAK12/2 compared to
PAK1+/+ mice (n = 6, Student’s T-test, p = 0.03). PAK3 protein
expression was not detected in hind-limb tissue, in agreement with
reports demonstrating that PAK3 is expressed only in mouse brain
tissue (Figure 3A) [41]. Surprisingly the increase in PAK2
expression was observed only in ischemic tissue whereas non-
ischemic tissue from PAK12/2 and PAK1+/+ mice expressed
similar levels of PAK2 (Figure 3B vs 3D). PAK2 activation was
determined by the ratio of phosphorylated (p) PAK2 to total
PAK2, and although pPAK2 levels also trended towards an
increase in PAK12/2 mice compared to PAK1+/+ mice, the
relative difference was not statistically significant (Figure 3C).
These results suggest that ischemia-specific upregulation of PAK2
expression is a potential compensatory mechanism in the chronic
absence of PAK1.
ERK1/2 but not AKT activation is involved in the potential
compensatory effect during HLI in PAK12/2 mice
Several studies have shown that PAKs are involved in the ERK-
signaling cascade by phosphorylating the ERK upstream mole-
cules, c-Raf and MEK1 [42,43]. PAKs also serve a scaffolding
function for both c-Raf/MEK1 and AKT/PDK1 complexes
[44,45]. Both ERK and AKT signaling pathways are linked to
endothelial cell proliferation, migration, and to the angiogenesis
process in general [46–48]. We therefore opted to examine
ERK1/2 and AKT activation in the gastrocnemius muscle of
ischemic and non-ischemic PAK12/2 and control mice after one
hour of HLI onset. We observed similar total ERK and AKT
protein levels in PAK12/2 and PAK1+/+ gastrocnemius muscle;
however activation of ERK1/2 (Thr202/Tyr204) was observed in
non-ischemic tissue from PAK12/2 tissue (Figure 4). In contrast,
changes in AKT activation, as assessed by the phosphorylation of
S473 and T308, were not observed.
Effect of inhibition of all group I PAK kinases on EC
sprouting from aortic rings
To determine if other PAK1 family members (e.g. PAK2)
compensated for PAK1 loss in another assay of endothelial
function, we used aortic ring EC sprouting assays. An equal
numbers of EC sprouts were observed in PAK1+/+ and PAK12/2
aortic rings (Figure 5A) and treatment with IPA3, an allosteric
inhibitor of group I PAKs, significantly inhibited sprout formation
in both sets of aortic rings (p = 0.0001, two-way ANOVA)
(Figure 5C). These data suggest that both PAK1 and PAK2 are
essential for EC sprouting and potentially neovascularization.
Effect of PAK1 loss on cutaneous wound healing
Ear wound assays are used to assess the migration and function
of fibroblasts, macrophages, epithelial cells and subsequent
capacity for wound repair and injury-induced capillary sprout-
ing/angiogenesis. In addition to its function in EC motility and
function, PAK1 has been shown to affect the function of some of
the aforementioned cell types involved in wound healing [49–51];
therefore, we sought to determine the in vivo effect of PAK1 on
cutaneous wound healing. The pattern of ear wound closure
following injury in PAK12/2 and PAK1+/+ mice was in
agreement with published work where wound diameter increases
slightly on day 7 and decreases thereafter; however, complete
closure is not achieved. Ear wound diameter decreased similarly to
50% by day 28 in both PAK12/2 and PAK1+/+ mice (Figure 6A).
Very similar tissue architecture was observed in the two groups by
day 28 as shown using Mason’s trichrome stain (Figure 6B).
Discussion
We originally hypothesized that loss of PAK1 would impair
ischemia-induced neovascularization based on our studies of the
CIB1/PAK1 signaling pathway [4,5]. In addition, PAK1 is
intimately linked to proper function and migration of a variety
of cell types such as macrophages [50], fibroblasts [49], endothelial
cells [1,2] and tumor cells [22]. We therefore sought to examine
the effect of chronic PAK1 loss on: 1) neovascularization, which is
dependent on endothelial cell migration and growth; and 2)
cutaneous wound healing, which involves migration of epithelial
cells and fibroblasts. Our results suggest that the ubiquitous PAK2
is likely to play an important compensatory role in neovascular-
ization in the absence of PAK1 through activation of the ERK-
PAK1 and PAK2 in Neovascularization and Wound Healing
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e112239
Figure 1. PAK12/2 plantar perfusion and function in model of severe HLI in 6–8 week-old mice is similar to PAK1+/+ mice. A) I/NI
(Ischemic/Non-Ischemic) plantar perfusion ratio is comparable between PAK12/2 and PAK1+/+ mice as measured by laser Doppler imaging from day
0, immediately after HLI surgery, and throughout the 21 days after HLI surgery. B) Limb use score was determined as described in Materials and
Methods and is equivalent between groups, where a higher score is observed within the first 2 weeks after surgery and decreased significantly
thereafter, and indicating recovery of limb function. C) Appearance scores of PAK1+/+ and PAK12/2 mice were not statistically significant. D) Laser
Doppler images obtained immediately following HLI surgery and on day 21 reflect a lack of difference in perfusion between PAK1+/+ (N = 8) and
PAK2/2 (N = 11) mice.
doi:10.1371/journal.pone.0112239.g001
Figure 2. PAK12/2 plantar perfusion and limb function following severe HLI in 16 week-old mice is slightly impaired compared to
PAK1+/+ mice, suggesting mild impairment in neovascularization in the absence of PAK1. A) I/NI foot perfusion ratio is similar between
PAK1+/+ and PAK12/2 mice immediately following surgery, but starts to diverge by days 3 and 7 days (B–C). Worse use and appearance scores in
PAK12/2 mice on days 7 and 14 reflect the overall impaired limb function due to impaired neovascularization. D) Laser Doppler images obtained on
day 0 pre- and post-surgery, and on day 21 showing similar perfusion between PAK12/2 (N = 8) and PAK1+/+ (N = 8) mice.
doi:10.1371/journal.pone.0112239.g002
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Figure 3. Increased protein expression and phosphorylation of PAK2 in ischemic gastrocnemius muscle in PAK12/2 compared to
PAK1+/+ mice. A) Western blots showing upregulated PAK2 expression and a trend towards increased phospho-PAK2 in PAK12/2 mice (lanes
represent samples from 3 different mice). We did not observe expression of PAK3 in gastrocnemius tissue; however, abundant PAK3 expression is
found in mouse brain tissue as can be seen from a positive control sample in lane 7 of the PAK3 blot. B–C) Densitometry analysis reveals a 2-fold
increase in PAK2 expression in PAK12/2 compared to PAK1+/+ mice, normalized to GAPDH as a loading control, and a concomitant increase in
phospho-PAK2 relative to total PAK2. *indicates p#0.05 using Student’s T-test, n = 6. D) Densitometric analysis of total PAK2 protein expression in
non-ischemic muscle did not reveal a change in PAK1+/+ versus PAK12/2 mice.
doi:10.1371/journal.pone.0112239.g003
Figure 4. A) A notable activation of ERK1/2 but not AKT is observed in PAK12/2 gastrocnemius tissue one hour after HLI surgery. Western blotting
analysis of PAK12/2 non-ischemic and ischemic gastrocnemius muscle shows enhanced phosphorylation of ERK1/2 on Thr202/Tyr204 compared to
PAK1+/+ tissue, whereas phosphorylation of AKT was unchanged. Lanes are grouped into Non-Ischemic and Ischemic from either PAK1+/+ and
PAK12/2 mice. B and D) Densitometric analysis of non-ischemic tissue from PAK1+/+ and PAK12/2 show an increase in pERK1/2 activation (p = 0.03
and 0.06 for pERK1 and pERK2 respectively, Student’s T-test) whereas a difference in pAKT activation is not observed. C and E) In ischemic tissue a
trend towards an increase in pERK1 (p = 0.08, Student’s T-test) but not pERK2 or pAKT in PAK12/2 compared to control PAK1+/+ was observed. A total
of 3 PAK1+/+ and PAK12/2 mice were analyzed. Blots for pERK1/2 and pAKT were normalized to tERK1/2 and tAKT respectively.
doi:10.1371/journal.pone.0112239.g004
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cascade. These results do not necessarily speak to a role for PAK1
in ischemia-induced neovascularization per se, since such a role
might be revealed upon more acute PAK1 inhibition or depletion.
A PAK1-specific pharmacologic inhibitor is not currently avail-
able. Our results do indicate, however, that chronic PAK1 absence
as in traditional knockout mice, results in elevated PAK2
expression during ischemic injury that could provide functional
compensation to preserve tissue perfusion and function. Inhibition
of EC sprouting with the group I PAK inhibitor IPA3 further
supports a role for PAK2 in sprouting angiogenesis.
Functional compensation between group I PAK members is not
surprising given that group 1 PAKs share 80–90% sequence
homology in their kinase domain and 88% homology in their p-21
binding domains (PBD) [41]. The signaling function of PAKs can
be independent of their kinase activity; thus, a group I member
can potentially compensate for the loss of PAK1 by activating
downstream targets or by acting as a scaffolding protein in a
signaling complex [52,53]. However, the loss of PAK2 in a
traditional knockout mouse results in embryonic lethality due at
least in part to improper vessel formation, suggesting the
indispensability of PAK2 in endothelial cell function [54]. Our
data are the first to suggest potential compensation between PAK1
and PAK2 in neovascularization. However, redundant functions
between other PAK members have been reported. Functional
redundancy between PAK1 and PAK3 is suggested by data from
individual knock-out animals [55]. PAK3 mutations in humans
leads to nonsyndromic mental retardation characterized by
selective cognition deficits [56,57]. Loss of PAK3 in mice has no
effect on brain or spine morphology and the mice have normal
basal synaptic strength; however, they have a deficit in the late
phase of long-term potentiation (L-LTP) [55]. This phenotype is
closely related to that seen in PAK12/2 mice [58]. Loss of both
PAK1 and PAK3 results in learning and memory deficits with
hyperactive behavior and lack of complexity in neuronal
Figure 5. Marked reduction in aortic EC sprouting following IPA3 treatment. A) Similar EC sprouting is observed in PAK12/2 and PAK+/+
aortic rings cultured for 5 days in growth media supplemented with FBS, whereas a notable reduction in sprouting was observed following 30 mM
IPA3 treatment. B) Magnification of the selected region showing EC sprouts (white arrows). C) Quantification of EC sprouts shows less EC sprouts in
PAK1+/+ and PAK12/2 with IPA3 treatment. Data points represent the average values 6SEM from 3–9 rings from 3–4 mice per group; * denotes p,
0.05 compared to FBS alone.
doi:10.1371/journal.pone.0112239.g005
Figure 6. Unimpaired repair of cutaneous ear wounds in
PAK12/2 mice. A) Recovery of 2.0 mm ear punch wounds is
represented by (Area day X/Area day 0) 6100. There was a notably larger
but not statistically significant wound diameter in PAK12/2 mice
compared to PAK1+/+ mice on day 7. B) The wound edge was stained
with Mason’s trichrome and shows a very similar wound closure
between the two groups by day 28. n = 3 for both PAK1+/+ and PAK12/2
groups.
doi:10.1371/journal.pone.0112239.g006
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morphology suggesting functional redundancy between PAK1 and
PAK3 [59]. Furthermore among group II PAKs, PAK5 and
PAK6 appear to have overlapping functions in the development of
the nervous system, whereby separate knockout of these individual
genes does not result in a significant phenotype but PAK5/6
double knockout mice present with deficits in learning as well as
locomotor activity [60,61].
Our results show a slightly reduced recovery of perfusion and
worse hindlimb ischemic appearance and functional use in
PAK12/2 mice at 16 weeks of age, compared to 6–8 week-old
mice. Impaired angiogenesis and collateral remodeling in ischemia
has been reported previously and linked to several cellular and
extracellular mechanisms [62–64]. Aging endothelial cells have a
reduced capacity for NO production and therefore enhanced
sensitivity to apoptotic cell death [65,66]. Furthermore, decreased
levels of certain miRNAs such as miRNA-217 and miRNA-146a
have been demonstrated to modulate senescence of endothelial
cells in vitro [67,68]. Extracellular factors modulating angiogenesis
in aging involve increased expression of TIMP-2 and altered
composition of the extracellular matrix [69]. A decrease in the
potent growth factors VEGF [62,70] and TGF-b [71] and an
increase in thrombospondin-2 [72] in aging endothelium affects
endothelial cell proliferation, migration, and matrix formation. In
studies using aged animals, reduced neovascularization capacity
was reported following stress or injury to the endothelium [70,73]
as well as in the non-injured endothelium [62]. The neovascular-
ization changes that we observe in slightly older PAK12/2 mice
are potentially due to several of the abovementioned factors
exacerbated by the absence of PAK1, not only in endothelial cells
but also in auxiliary cells such as smooth muscle cells, fibroblasts
and immune cells where PAK1 might be indispensable and where
PAK2 cannot substitute for its function Interestingly, PAK1 and
PAK2 appear to participate in distinct signaling cascades and in
some cases play opposing roles in mast [74], breast [75], and
prostate [76] carcinoma cells. Whereas PAK1 is a positive
modulator of mast cell degranulation through regulation of
calcium influx [34], PAK2 is a negative regulator of degranulation,
and independent of calcium influx [74]. Furthermore PAK1 and
PAK2 appear to have opposing effects on modulating the
phosphorylation of MLC and focal adhesions in tumor cells
[75]. PAK1 appears to have a pro-adhesion, -migration and -
proliferation response whereas PAK2 appears to inhibit these
processes.
As mentioned above, PAKs are involved in the activation of the
canonical ERK-signaling cascade, which has long been recognized
as essential for angiogenesis [77]. Several studies including our
own link PAK1 to ERK1/2 [5,44,50]. Loss of PAK1 results in
downregulation of ERK activity with negative effects on cell
motility/migration [29,78], and proliferation [79]. Furthermore,
PAK1 activation induced by adhesion to matrix proteins activates
the MAPK signaling cascade and is thought to be a convergence
site between integrins and growth factor signaling [80,81].
However few reports exist on the role of PAK2 in MAPK-
signaling and even fewer reports examine the functional signifi-
cance of PAK2/MAPK signaling. Among these studies are ones
examining the role of PAK2 in hematopoietic stem cell function
through its phosphorylation of ERK [82] Specifically PAK2 is an
essential effector of TGFb signaling and ERK-mediated tran-
scriptional response [83]. Our results suggest in accordance with
some of these previous studies that PAK2 can potentially lead to
ERK activation to modulate the physiological angiogenesis
response.
Limitations of this investigation stem from the presence of
compensatory mechanisms that preclude studying the effect of
PAK1 in vivo on physiological processes that depend on normal
cell migration. One way to circumvent this problem is to generate
a double inducible, conditional knockout mouse lacking PAK1 in
addition to PAK2, where selectivity for time and location of gene
knockdown can be controlled by the investigator. A conditional
knockout approach would circumvent the difficulty of deletion of a
gene essential for mouse development and allow the examination
of gene products in the adult mouse under stress conditions. In
addition, this strategy would permit investigation of the specific
cell type responsible for the phenotype. However, even with this
strategy, compensation is still possible if altered gene expression
occurs quickly. With the present study we are reminded of the
outstanding ability of biological systems to adjust to environmental
and genetic challenges. Systems perturbations that target vital
components to development or response to injury will perturb the
system; however, genetic redundancy can completely mask these
changes. Our study also sheds light on the discord often
encountered between conclusions drawn based on studies done
in vitro and those ascertained from testing in complex organisms.
The discord is partly due to an incomplete but growing knowledge
of key players and mechanisms of ischemia and neovasculariza-
tion. The advancement in targeted gene deletion technology and/
or targeted pharmacological inhibitors has the potential to allow us
to elucidate these mechanisms and identify all the important
players throughout the different stages of neovascularization.
Supporting Information
Figure S1 Schematic of surgical procedures used in the
study. Q denotes ligation sites and « denotes cutting sites. A)
Severe HLI model involves ligation of the femoral artery distal to
the inguinal ligament and proximal to the bifurcation of the
popliteal artery. The artery was transected between the ligation
points; in addition the superficial epigastric artery was ligated. B)
Mild HLI model consisting of ligation and transection between the
lateral caudal femoral artery and proximal to the bifurcation of the
popliteal artery, plus ligation of the superficial epigastric.
(TIF)
Figure S2 PAK12/2 neovascularization is unimpaired
following mild HLI. A and D) I/NI perfusion ratios are almost
identical after mild HLI in PAK1+/+ and PAK12/2 mice. B–C)
Use and appearance scores that are not statistically different are in
agreement with the perfusion ratio observation and confirm the
lack of difference in ischemic limb function between PAK12/2
and PAK1+/+ mice (n = 7 for PAK1+/+ and n = 10 for PAK12/2).
(TIF)
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